Astellas Pharma confirms interim analysis of Xtandi study to occur this year


Astellas Pharma (ALPMY.PK +1.2%) corrects a translation error in its FQ1 conference call earlier, confirming that interim analysis on its Prevail study of Xtandi will actually occur this year.

The company became aware of an error in the English translation, which cited incorrect timing of the interim analysis.

Guidance has not changed.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs